Events Speakers Talks
 

Speakers

Sort by
Newest
Trending
31-48 of 48
Filter
Joshua Jones
Founder at Jonesing Labs
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Julie P. Fry
Cannabis Industry Consultant
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Tyrell Towle
Director of Chemistry at MedPharm Holdings
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Sean Colvin
Senior Scientist at TreeHouse Biotech
alternative medicine, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis (drug), crohn's disease, drink, endocannabinoid system, entourage effect, gpr55, hash oil, immune system, immunodeficiency, liquor, moonshine, neuron, pharmaceutical industry, pharmacology, prohibition, receptor (biochemistry), tetrahydrocannabinol, weight training
Jake Black
Chief Scientific Officer at Treehouse Biotech
accuracy and precision, analgesic, anesthesia, animal testing, aromatherapy, attention, big data, biochemistry, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis, cannabis (drug), cannabis indica, cannabis sativa, cannabis strain, carbon dioxide, carboxylic acid, cell (biology), certificate of analysis, certification, chemistry, chemotherapy, chromatography, circulatory system, cocaine, court, data, dietary supplement, dose (biochemistry), drug overdose, drug rehabilitation, drug test, electric battery, electronic cigarette, endocannabinoid system, entourage effect, enzyme, essential oil, ethanol, food, food and drug administration, fungus, gas chromatography, glyphosate, greenhouse gas, hemp, herb, herbal medicine, inquiry, international organization for standardization, iso/iec 17025, kashrut, life, lipid bilayer, major depressive disorder, mass, measurement uncertainty, medical cannabis, medication, mercury (element), mood (psychology), mood disorder, natural product, nutrient, odor, olfaction, opiate, opioid, over-the-counter drug, pain, pain management, parts-per notation, perfume, personalized medicine, pesticide, pesticide residue, pharmaceutical industry, pharmacology, placebo, prescription drug, product liability, propagation of uncertainty, protein structure, protein structures, protein-protein interaction, protein–protein interaction, quantification (science), regulatory compliance, reliability engineering, reputation, research, science, solvent, stress (biology), substance dependence, tablet (pharmacy), tetrahydrocannabinol, tetrahydrocannabinol acid, traceability, uncertainty, united states pharmacopeia, validity (statistics), vaporizer (inhalation device), vitamin, water, whole foods market
Kurt Levy
Senior Research Scientist at Canopy Growth Corporation
bioavailability, cannabinoid, cannabinoid receptor type 1, cannabis, chemical bond, chemical polarity, chromatography, distillation, dose (biochemistry), high-performance liquid chromatography, hydrophile, liquid–liquid extraction, medical cannabis, modified-release dosage, neurotransmitter, pharmacodynamics, pharmacokinetics, phospholipid, psychopharmacology, receptor (biochemistry), receptor antagonist, synthetic cannabinoids, taste, tetrahydrocannabinol, thin-layer chromatography
James Schwartz
CEO at Cascade High
agriculture, antibiotic, aromatherapy, bacteria, bank, brand, california, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinoids, cannabinol, cannabis, cannabis (drug), cannabis indica, cannabis sativa, certificate of analysis, charlotte's web (cannabis), clinical trial, coeliac disease, compost, convenience store, counterfeit consumer goods, crop insurance, curriculum, dietary supplement, distribution (marketing), dose (biochemistry), due diligence, ecosystem, electronic cigarette, endocannabinoid system, endocrine system, evidence-based medicine, farmer, fertilizer, finance, food, food and drug administration, gardening, gene, genetically modified crops, genetically modified food, genetically modified organism, genetics, gluten, gluten-related disorders, glyphosate, glyphosates, go to market, good manufacturing practice, health care, hemp, homeostasis, integrated pest management, irritable bowel syndrome, lawyer, maize, mediation, medical cannabis, medical prescription, medication, natural environment, nervous system, nothing, online advertising, organic certification, organic farming, organic matter, organized crime, overtime, packaging and labeling, packaging, and labeling, pain management, pansy, password, patient, payment, pest control, pesticide, pharmaceutical industry, placebo-controlled study, plant breeding, plastic, prescription drug, pricing, psychoactive drug, question, recycling, retail, safety, sampling (statistics), self-medication, shelf life, smoking, social media, soil, supply chain, sustainability, sustainable agriculture, sympathetic nervous system, tetrahydrocannabinol, titanium, tomato, traceability, tree, united states department of agriculture, united states postal service, vaporizer (inhalation device), water content
David Ostrow
Director at David Ostrow & Associates
allosteric regulation, alzheimer's disease, anxiolytic, brain, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabinoid receptor type 2, cell nucleus, channel blocker, endocannabinoid system, gene expression, hiv/aids, homeostasis, ligand (biochemistry), medical cannabis, medication, nervous system, neuron, organism, pharmacology, receptor antagonist, relapse, stimulus (physiology), tetrahydrocannabinol
Hervé Damas
Founder & CEO at Dr. Damas Wellness
action potential, allosteric modulator, autoimmune disease, axon, axon terminal, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 1 can, chemical synapse, depolarization, depressant, dopamine, entourage effect, epilepsy, epileptic seizure, gamma-aminobutyric acid, glutamic acid, monosodium glutamate, neuron, neurotransmitter, receptor antagonist, reuptake, selective serotonin reuptake inhibitor, synapse, tetrahydrocannabinol
Jessica Barnes
CEO & Co-founder at 20Lighter Program
aspirin, bioavailability, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabis, cannabis (drug), dietary supplement, direct-to-consumer advertising, endocannabinoid system, first, pass effect, food and drug administration, gastrointestinal tract, hemp, in vitro, intravenous therapy, micro-encapsulation, nanoparticle, nutraceutical, pharmaceutical industry, pharmacology, route of administration, steve jobs, tetrahydrocannabinol, toxicity
Todd Griffin
Chief Technical Officer at G2 Analytical
aspirin, bioavailability, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabis, cannabis (drug), dietary supplement, direct-to-consumer advertising, endocannabinoid system, first, pass effect, food and drug administration, gastrointestinal tract, hemp, in vitro, intravenous therapy, micro-encapsulation, nanoparticle, nutraceutical, pharmaceutical industry, pharmacology, route of administration, steve jobs, tetrahydrocannabinol, toxicity
William Fisher
Board Chairman at Diverse Biotech
appetite, aspirin, bioavailability, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabis, cannabis (drug), chemotherapy, clinical trial, dementia, dietary supplement, direct-to-consumer advertising, dose (biochemistry), drug development, endocannabinoid system, fibromyalgia, first, pass effect, food and drug administration, gastrointestinal tract, headache, hemp, in vitro, inflammation, intravenous therapy, micro-encapsulation, nanoparticle, nutraceutical, opioid epidemic in the united states, personalized medicine, pharmaceutical industry, pharmacogenomics, pharmacology, pharmacy, placebo, route of administration, sensitivity and specificity, steve jobs, synthetic cannabinoids, tetrahydrocannabinol, toxicity
Shari Campbell
Lead Chemist at Kaycha Labs
aspirin, bioavailability, brand, cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabinoids, cannabis, cannabis (drug), certified reference materials, clinical trial, dairy, dietary supplement, direct-to-consumer advertising, endocannabinoid system, first, pass effect, food, food and drug administration, gastrointestinal tract, good manufacturing practice, hemp, high-performance liquid chromatography, in vitro, intravenous therapy, medical device, micro-encapsulation, nanoparticle, nuclear magnetic resonance, nutraceutical, packaging and labeling, pharmaceutical industry, pharmacology, protocol (science), quality assurance, quality management system, research, retail, route of administration, shelf life, standard deviation, steve jobs, tetrahydrocannabinol, toxicity, uncertainty
August Dunning
Chief Science Officer at Eco Research LLC
alternative medicine, appetite, cancer, candida (fungus), cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabis (drug), cannabis indica, chemotherapy, dose (biochemistry), endocannabinoid system, endocrinology, epilepsy, food and drug administration, hormone, obesity, probiotic, selective serotonin reuptake inhibitor, sleep, synthetic cannabinoids, tetrahydrocannabinol, traditional chinese medicine, vitamin c, well-being
Steve Kazemi
COO at Precision Plant Molecules
alternative medicine, appetite, cancer, candida (fungus), cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabis (drug), cannabis indica, chemotherapy, dose (biochemistry), endocannabinoid system, endocrinology, epilepsy, food and drug administration, hormone, obesity, probiotic, selective serotonin reuptake inhibitor, sleep, synthetic cannabinoids, tetrahydrocannabinol, traditional chinese medicine, vitamin c, well-being
Graciela Moreno
Director of Member Engagement at CBD Industry Association
alternative medicine, anti-inflammatory, appetite, audit, board certification, bong, brand, cancer, candida (fungus), cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabis, cannabis (drug), cannabis indica, cannabis industry, cannabis sativa, central processing unit, chemotherapy, convertible bond, cosmetics, crowdfunding, debenture, debt, dietary supplement, discounting, dispensary, dose (biochemistry), dravet syndrome, education, emergency medical technician, endocannabinoid system, endocrinology, epilepsy, fda food safety modernization act, financial capital, food, food and drug administration, food safety, free market, good manufacturing practice, hair loss, health claim, hormone, interest, interest rate, investment, investor, iso 9000, kentucky, medical cannabis, medical school, medication, medicine, mental disorder, mental health, mergers and acquisitions, mind, nsf international, nursing, obesity, ondansetron, opiate, option (finance), organic certification, over-the-counter drug, paramedic, pathology, pediatrics, physician, prescription drug, probiotic, psychopharmacology, quality management system, regulatory compliance, research, retail, safety, schizophrenia, selective serotonin reuptake inhibitor, sleep, social stigma, specialty (medicine), stock, stock dilution, substance abuse, syndrome, synthetic cannabinoids, tetrahydrocannabinol, therapy, tony montana, traditional chinese medicine, valuation (finance), verification and validation, vitamin c, well-being
Rob Streisfeld
CEO at BeyondBrands
absorption (pharmacology), allergy, alternative medicine, appetite, bioavailability, cancer, candida (fungus), cannabidiol, cannabinoid, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabis, cannabis (drug), cannabis indica, chemotherapy, chronic stress, cortisol, crohn's disease, cytokine, dose (biochemistry), endocannabinoid system, endocrinology, epilepsy, food allergy, food and drug administration, gastrointestinal tract, grapefruit–drug interactions, herbal medicine, hormone, hypertension, obesity, opioid, pain, probiotic, route of administration, selective serotonin reuptake inhibitor, sleep, stress (biology), synthetic cannabinoids, tetrahydrocannabinol, therapy, traditional chinese medicine, tumor necrosis factor-alpha, vitamin c, well-being
Carter Baird
R&D Laboratory Technician at United Cannabis Corporation
absorption (pharmacology), alternative medicine, bioavailability, blood sugar level, cannabidiol, cannabinoid, cannabinoid receptor, cannabinoid receptor type 1, cannabinoid receptor type 2, cannabinol, cannabis, cannabis (drug), chemist, concussion, crohn's disease, cytochrome p450, dose (biochemistry), drink, emotion, endocannabinoid system, entourage effect, enzyme, gpr55, hash oil, immune system, immunodeficiency, liposome, liquor, memory, micelle, milk, moonshine, nanotechnology, neuroimaging, neuron, pharmaceutical industry, pharmacokinetics, pharmacology, prohibition, receptor (biochemistry), receptor antagonist, surfactant, tetrahydrocannabinol, weight training
1 2